### Contents

**Perspective**
33  mHealth in psychiatry: time for methodological change

**Clinical reviews**
35  Ketamine for treatment-resistant depression: recent developments and clinical applications
39  Are all psychotherapies equally effective in the treatment of adult depression? The lack of statistical power of comparative outcome studies
43  Computerised cognitive behaviour therapy for major depression: a reply to the REEACT trial

**Evidence-based case conference**
46  Diagnosing autism spectrum disorder (ASD) among adults

**Statistics in practice**
49  Economic evaluation of mental health interventions: an introduction to cost-utility analysis

**Causes and risk factors**
54  High-potency cannabis increases the risk of psychosis
55  Impact of additive alcohol and substance use disorders on the mortality of people with schizophrenia and mood disorders
56  Support for the link between adolescent mental health problems and subsequent perinatal depression: a 20-year prospective cohort study

**Outcomes**
57  Treatment of maternal perinatal depression in a low-income setting does not lead to improved outcomes for children
58  Psychotic disorders cause the greatest mortality disparity among mental disorders, though more deaths are attributable overall to mood and anxiety disorders

**Miscellaneous**
59  A negative randomised sham-controlled trial of ventral capsule/ventral striatum stimulation in treatment-resistant depression: an unsuccessful trial or treatment?

**Pharmacological interventions**
60  Alpha-7 nicotinic agonist improves cognition in schizophrenia
61  Lack of improvement at week 2 predicts later antipsychotic non-response in people with acute exacerbations of schizophrenia or schizophrenia-like psychosis
62  Unnecessary psychotropic drug prescription in primary care for people with intellectual disability

**Psychological interventions**
63  Psychodynamic therapy: a poorly defined concept with questionable evidence

**Letter**
64  Psychodynamic therapy: a well-defined concept with increasing evidence

**Electronic pages**

| e6 | Which role for brexpiprazole, a new dopamine D2 partial agonist, in the treatment of schizophrenia? |
| e7 | Some augmentation strategies improve outcome but increase discontinuation in adults with treatment-resistant depression |
| e8 | Long-acting injectable risperidone as an option in first-episode psychosis |
| e9 | Clonidine: new use of an old medication to reduce stress-related substance use |

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (www.publicationethics.org)